Ajanta Pharma share news, announcements and annual reports
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,508.80up ₹49.10 (1.42%)BSE ₹3,512.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,459.70.
30 Oct: open ₹3,479.00, high ₹3,619.90, low ₹3,460.50
52-week range of traded prices to 30 Oct 2026
₹2,430.00Low, 30 Oct 2025₹3,796.00High, 18 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43,846 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.72
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.02
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 30.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,55826.6% delivered
Ajanta Pharma share news and announcements
812 announcements, routine notices left out, newest first. Page 8 of 17.
Jul 2019
19 Jul · Board meeting
18 Jul · Meeting
Jun 2019
May 2019
31 May · Disclosure
29 May · Related Party Transactions
Apr 2019
30 Apr · Board meeting
30 Apr · Results
19 Apr · Board meeting
Mar 2019
25 Mar · Post Buyback Public Announcement
Feb 2019
25 Feb · Updates
1 Feb · Public Announcement - Buyback of Shares
Jan 2019
31 Jan · Corporate action
30 Jan · Board meeting
30 Jan · Board meeting
30 Jan · Results
21 Jan · Board meeting
Nov 2018
Oct 2018
31 Oct · Disclosure
31 Oct · Results
Sep 2018
14 Sep · Disclosure
Aug 2018
Jul 2018
31 Jul · Results
31 Jul · Board meeting
27 Jul · Updates
20 Jul · Board meeting
13 Jul · Legal
Exchange has sought clarification from the Company with respect to news item captioned- Ajanta Pharma Drug control In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.6 Jul · Meeting
Jun 2018